So no good results worth sharing then
Subramaniam SR, Chesselet MF (2013) Mitochondrial dysfunction and oxidative stress in Parkinsons disease
For example, if you started a GLP-1 in September 2024 with a BMI of 37 but in July 2026 youve lost weight and now have a BMI of 34, the prescriber should attest in the prior authorization request that you met the BMI criteria of 35 or over when the GLP-1 therapy started
The GoodRx price doesn't count toward your insurance deductible, so if you're trying to meet a deductible, paying Costco's member price may be strategically better
The data in the FAERS database covered from the second quarter of 2022 (the quarter in which tirzepatide was approved by the FDA) to the third quarter of 2024 (the most recent quarter available at the start of this study, posted on 30-Oct-2024)
Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes